MEDICAL DISCLAIMER: Educational research guidelines only. Lyophilized peptides are investigational chemical compounds and are NOT approved for human consumption, diagnosis, or therapy. Consult a licensed physician before any research application.
P21 Dosage Chart, Schedule & Reconstitution Protocol
Quickstart Highlights
P21 (P021) is a CNTF-derived neurotrophic peptide mimetic, sequence Ac-DGGL(A)G-NH2, engineered by Khalid Iqbal's group from the active region of ciliary neurotrophic factor and stabilized with an adamantyl group so it is orally bioavailable and crosses the blood-brain barrier. It boosts adult hippocampal neurogenesis and synaptic plasticity by partially inhibiting leukemia inhibitory factor (LIF) signaling and raising BDNF, which lowers GSK-3β activity and abnormal tau phosphorylation (PMID 25046994). In rodent Alzheimer's, aging, and neurodevelopmental models it restored memory, dendritic density, and neurogenesis without weight loss (PMID 28655344). Researchers study it for neurodegeneration, cognitive aging, and synaptic repair. Crucially, there are no human trials, all dosing in studies was oral/dietary, and it is not approved by any regulator — the injectable figures used on this site are an educational measurement model only, not a validated human protocol.
Reconstitute: Add 2 mL bacteriostatic water → 5 mg/mL concentration.
Easy measuring: At 5 mg/mL, 1 unit = 0.01 mL = 0.0500 mg (50 mcg) on a U-100 insulin syringe.
Storage: Lyophilized powder stored frozen or refrigerated; reconstituted solution refrigerated at 2–8°C and used within several weeks. Avoid repeated freeze–thaw cycles and protect from light.
Half-life: Human half-life unknown; in rodents the adamantane group extends plasma half-life into the multi-hour range (cited as greater than 3–6 hours) versus roughly 3 minutes for native CNTF.
Route: Oral (dietary) in all published studies; intranasal in some community use. No validated injectable route — the subcutaneous reconstitution here is an educational measurement model.
Status: Not FDA, EMA, or MHRA approved. Preclinical research compound only, with no human clinical trials; sold strictly as a research chemical.
About P21
P21 (P021) is a CNTF-derived neurotrophic peptide mimetic studied in rodent models of Alzheimer's disease, brain aging, and neurodevelopmental disorders, where chronic treatment increased hippocampal neurogenesis, restored dendritic and synaptic density, and rescued memory without affecting body weight [1][2]. It was engineered from the active region of ciliary neurotrophic factor and stabilized with an adamantyl group so it survives the gut and crosses the blood-brain barrier [3].\n\nImportant route note: in every published study P21 was administered ORALLY (mixed into the diet); some community users instead take it intranasally. There is no human injectable protocol. The subcutaneous figures below are an educational reconstitution reference built to mirror this site's other entries and to make doses measurable on a standard insulin syringe — they are not a validated human P21 dosage and not medical advice.\n\nThis guide presents a practical dilution so research dose units land cleanly on a U-100 syringe. Because no clinical human dose has been established, the modeled amounts (roughly 250–1000 mcg per administration) are extrapolations only and should be read as educational, not prescriptive [1][4].\n\nFrequency: Inject once daily subcutaneously (educational model). Preclinical dosing was continuous daily oral exposure; community oral/intranasal use is also typically once daily.
Quick Protocol Navigation
Reconstitution Instruction & Mixing Step-by-Step
Lyophilized powder must be reconstituted carefully. Agitating peptide chains can shear disulfide bonds and render the peptide biologically inert.
Draw 2.0 mL of bacteriostatic water into a sterile syringe (this yields 5 mg/mL, so 500 mcg = 10 units on a U-100 syringe).
Swab the vial stopper with alcohol, then inject the water slowly down the inner glass wall rather than directly onto the powder to avoid foaming.
Gently swirl or roll the vial until fully dissolved; do not shake, as agitation can degrade the peptide. The solution should be clear and colorless.
Swab the chosen rotation site, draw the prescribed unit volume, and inject slowly into subcutaneous tissue (this is an educational model; clinically P21 was dosed orally).
Wait a few seconds before withdrawing the needle, then re-cap and refrigerate the vial at 2–8°C between uses.
Interactive P21 Syringe Calculator
Currently visualizing the 10 mg vial reconstituted with 2 mL bacteriostatic water. Adjust the target dose to dynamically render syringe units.
Reconstitution Calculation: 10mg dry powder in 2mL water yields 5.00 mg/mL. To evaluate a 250mcg dose, pull to 5.0 units (5 syringe ticks).
U-100 Syringe Representation
Educational reference visual. Assumes standard U-100 insulin syringe where 1.0 mL volume = 100 units.
Titration & Dose Escalation Schedules
| Phase | Dose per injection | Units (per injection) |
|---|---|---|
| Weeks 1–2 (acclimation, educational model) | 250 mcg | 5 units (0.05 mL) |
| Weeks 3–6 (standard research range) | 500 mcg | 10 units (0.10 mL) |
| Weeks 7+ (upper research range) | 1000 mcg (1 mg) | 20 units (0.20 mL) |
Administration guidelines: Refer to guidelines | 2 mL Reconstitution
Research Supplies Quantity Planner
Scientific mathematical planning of syringes, bacteriostatic water and dry vials needed for extended research blocks using the 10 mg vial.
Peptide Vials (P21, 10 mg each):
- check8-week educational course (titrating 250→500→1000 mcg/day): ≈ 4 vials
- check12-week course: ≈ 6 vials
- check16-week course: ≈ 8–9 vials
Insulin Syringes (U-100):
- checkPer week: 7 syringes (1/day)
- check8 weeks: 56 syringes
- check12 weeks: 84 syringes
- check16 weeks: 112 syringes
Bacteriostatic Water (10 mL bottles): Use 2 mL per vial for reconstitution.
- check8 weeks (4 vials): 8 mL → 1 × 10 mL bottle
- check12 weeks (6 vials): 12 mL → 2 × 10 mL bottles
- check16 weeks (9 vials): 18 mL → 2 × 10 mL bottles
Alcohol Swabs: One for the vial stopper + one for the injection site each day.
- checkPer week: 14 swabs (2/day)
- check8 weeks: 112 swabs → 2 × 100-count boxes
- check12 weeks: 168 swabs → 2 × 100-count boxes
- check16 weeks: 224 swabs → 3 × 100-count boxes
Mechanism of Action (MOA)
P21 is a rationally designed mimetic of ciliary neurotrophic factor (CNTF), a gp130-family cytokine that supports neuronal survival and adult neurogenesis but is too large and unstable to use as a drug. Iqbal and colleagues mapped the neurotrophic activity of CNTF to a short C-terminal active region (the parent "Peptide 6" sequence) and then minimized it to the DGGL tetrapeptide pharmacophore corresponding to CNTF residues 147–150 [4]. To make this fragment drug-like, they N-acetylated and C-amidated it and attached an adamantylated glycine, giving the final compound Ac-DGGL(A)G-NH2. The bulky lipophilic adamantane cage sterically shields the peptide from exopeptidases, confers resistance to gastric acid, and dramatically improves lipophilicity so the molecule is orally bioavailable and crosses the blood-brain barrier — properties native CNTF lacks [3].\n\nMechanistically, P21 does not simply add a growth-factor signal; it relieves an endogenous brake on neurogenesis. CNTF and the related cytokine leukemia inhibitory factor (LIF) compete for shared gp130 receptor components. LIF signaling biases neural stem cells away from neuronal differentiation, so by partially and competitively inhibiting LIF signaling, P21 disinhibits the neurogenic program in the hippocampal dentate gyrus [3][5]. Downstream, P21 increases expression of brain-derived neurotrophic factor (BDNF). Elevated BDNF activates TrkB signaling, which inhibits glycogen synthase kinase-3 beta (GSK-3β). Because GSK-3β is a major tau kinase, this cascade reduces abnormal tau hyperphosphorylation and, in transgenic models, lowers soluble amyloid-beta — linking the peptide's neurogenic action to disease-modifying effects on Alzheimer-type pathology [1]. The net cellular result is increased proliferation and survival of new dentate granule neurons, greater dendritic arborization and spine density, restored synaptic protein expression, and improved long-term potentiation [2].\n\nPharmacokinetically, the adamantane modification extends plasma half-life into the multi-hour range in rodents (monographs cite values greater than three to six hours), compared with roughly three minutes for recombinant CNTF; the compound was effective when delivered chronically in the diet, confirming meaningful oral absorption and central exposure [3][6]. Notably, unlike systemic CNTF — which causes cachexia and weight loss — chronic P21 produced no weight loss, tumors, or overt toxicity over 18-month dosing in mice, suggesting the LIF-directed mechanism avoids the appetite-suppressing CNTF/leptin axis [2]. It is essential to state plainly that all of this pharmacology is preclinical: no human pharmacokinetic, bioavailability, or half-life data exist, and the route in every published study was oral, not subcutaneous. The injectable reconstitution model in this entry is an educational measurement convention only.
Clinical Trial Efficacy Highlights
- starThere are no human clinical trials of P21; the entire evidence base is preclinical, originating almost entirely from Khalid Iqbal's laboratory and collaborators, and every efficacy claim below derives from rodent studies [5].
- starIn the triple-transgenic (3xTg-AD) mouse model, 12 months of chronic ORAL P21 (started at 9–10 months of age) rescued deficits in cognition, neurogenesis, and synaptic plasticity, reduced hyperphosphorylated tau, and significantly lowered soluble amyloid-beta — effects attributed to increased BDNF expression and decreased GSK-3β activity [1].
- starBaazaoui and Iqbal showed that dietary P21 (60 nmol/g feed) given to 3xTg-AD mice from 3 months through 18–21 months of age prevented dendritic and synaptic deficits, boosted dentate gyrus neurogenesis, and preserved spatial memory, supporting a preventive/disease-modifying profile when started before overt pathology [2].
- starAn earlier foundational study established that the CNTF active-region peptide approach reversed neurogenic and neuroplastic abnormalities and cognitive impairment in 3xTg-AD mice without changing amyloid or tau burden, indicating the neurogenic/synaptic mechanism is sufficient to improve function independent of plaque clearance [4].
- starIn a sporadic-Alzheimer rat model produced by AAV-mediated overexpression of the PP2A inhibitor I2PP2A, chronic oral P21 reduced tau pathology and rescued learning and memory, extending efficacy beyond familial-AD transgenic models to a non-genetic disease model [3].
- starIn normal cognitive aging, administration of the neurogenic/neurotrophic compound P21 attenuated age-dependent decline in learning and memory in aged rats, suggesting effects on brain aging that are not specific to Alzheimer pathology [6].
- starChronic P21 treatment also inhibited age-related macular degeneration-like retinal pathology in aged rats and 3xTg-AD mice, illustrating that the neurotrophic/neurogenic mechanism affects CNS tissue beyond the hippocampus [7].
- starAcross these studies P21 produced no weight loss, tumors, or signs of pain over dosing periods up to 18 months, a tolerability signal that distinguishes it from native CNTF — but this remains animal-only safety data with no human confirmation [2].
Side Effects & Tolerability Profile
Clinical subjects transiently report mild side effects. Slowly escalating the titration dose represents the single most effective intervention to limit side effects.
- warningNo human safety data exist. P21 has never been formally tested in people, so its adverse-effect profile, drug interactions, and long-term risks in humans are unknown; all tolerability information comes from rodents.
- warningIn animal studies P21 was well tolerated over long dosing periods (up to 18 months) with no reported weight loss, tumor formation, or signs of pain or distress, but absence of toxicity in mice does not guarantee human safety [2].
- warningBecause the compound modulates LIF/CNTF cytokine signaling, BDNF, and neural stem-cell proliferation, theoretical concerns include effects on cell proliferation and on other gp130-dependent tissues; these have not been characterized in humans.
- warningRoute mismatch is a practical hazard: published efficacy used oral (dietary) dosing, and community use is often oral or intranasal. The subcutaneous figures here are an educational measurement model, not evidence that injection is safe or effective.
- warningResearch-grade material is not manufactured to pharmaceutical standards; impurities, inaccurate peptide content, and endotoxin contamination are realistic risks with gray-market product, and sterility cannot be assumed for any injectable preparation.
- warningStandard injection-related effects apply to any reconstituted subcutaneous use: local redness, bruising, irritation, or infection at the site if aseptic technique is not followed.
- warningUse is not advised in pregnancy, lactation, in people with active or prior malignancy, or in children, given the proliferative/neurodevelopmental mechanism and the complete lack of human data.
- warningRegulatory status: P21 is not approved by the FDA, EMA, MHRA, or any other authority for human use. It is an unapproved research chemical, and nothing here should be interpreted as medical advice or an endorsement of human use.
Subcutaneous Injection Technique
Most research peptides require subcutaneous injection into fatty tissue. Never inject directly into a blood vessel or deep muscle tissue unless clinically detailed.
1. Site Selection
Common locations include the abdomen (2 inches from navel), outer upper arms, or thighs.
2. Sanitization
Thoroughly clean the selected site, stopper and vial top using 70% isopropyl alcohol prep swabs.
3. Angle & Push
Pinch the skin and insert the needle at a 45 to 90-degree angle. Depress plunger smoothly.
4. Site Rotation
Rotate injection sites continuously to avoid lipodystrophy or tissue scarring.
Frequently Asked Questions
What is the typical P21 dosage?expand_more
There is no established human P21 dosage because no clinical trials have been conducted. In rodent studies it was given orally in the diet (about 60 nmol per gram of feed). Community oral or intranasal use trends toward roughly 0.5–1 mg per day. The 250–1000 mcg per-administration figures in this guide are an educational subcutaneous reconstitution model only, not a validated dose.
Is P21 FDA approved?expand_more
No. P21 (P021) is not approved by the FDA, EMA, MHRA, or any other regulator for human use. It has never advanced to human clinical trials and remains a preclinical research compound sold only as a research chemical. Nothing in this entry is medical advice.
How is P21 actually taken, and why does this page show injections?expand_more
In every published study P21 was administered orally (mixed into food); some community users take it intranasally. There is no human injectable protocol. This page models a subcutaneous reconstitution to match the site's format and make doses measurable on an insulin syringe, but the real-world research route is oral.
How do you reconstitute P21?expand_more
In this educational model, add 2 mL of bacteriostatic water to a 10 mg vial to make 5 mg/mL. At that concentration, 500 mcg equals 10 units (0.10 mL) on a U-100 syringe. Inject the water down the vial wall, swirl gently without shaking, and refrigerate the reconstituted solution at 2–8°C.
What is the half-life of P21?expand_more
Human half-life is unknown. In rodents the adamantane modification extends plasma half-life into the multi-hour range (monographs cite greater than three to six hours), compared with roughly three minutes for native CNTF. The compound was effective with continuous daily oral dosing, consistent with meaningful oral absorption and central nervous system exposure.
Related Guides & Tools
Step-by-step references for reconstituting, measuring, and storing P21, plus the universal dosing calculator.
Academic References & Study Citations
Kazim SF, Blanchard J, Dai CL, Tung YC, LaFerla FM, Grundke-Iqbal I, Iqbal K. Disease modifying effect of chronic oral treatment with a neurotrophic peptidergic compound in a triple transgenic mouse model of Alzheimer's disease. Neurobiol Dis. 2014;71:110-130. View Scientific Paper →
Baazaoui N, Iqbal K. Prevention of dendritic and synaptic deficits and cognitive impairment with a neurotrophic compound. Alzheimers Res Ther. 2017;9(1):45. View Scientific Paper →
Bolognin S, Blanchard J, Wang X, Basurto-Islas G, Tung YC, Kohlbrenner E, Grundke-Iqbal I, Iqbal K. An experimental rat model of sporadic Alzheimer's disease and rescue of cognitive impairment with a neurotrophic peptide. Acta Neuropathol. 2012;123(1):133-151. View Scientific Paper →
Blanchard J, Wanka L, Tung YC, Cárdenas-Aguayo Mdel C, LaFerla FM, Iqbal K, Grundke-Iqbal I. Pharmacologic reversal of neurogenic and neuroplastic abnormalities and cognitive impairments without affecting Aβ and tau pathologies in 3xTg-AD mice. Acta Neuropathol. 2010;120(5):605-621. View Scientific Paper →
Kazim SF, Iqbal K. Neurotrophic factor small-molecule mimetics mediated neuroregeneration and synaptic repair: emerging therapeutic modality for Alzheimer's disease. Mol Neurodegener. 2016;11(1):50. View Scientific Paper →
Bolognin S, Buffelli M, Puoliväli J, Iqbal K. Rescue of cognitive-aging by administration of a neurogenic and/or neurotrophic compound. Neurobiol Aging. 2014;35(9):2134-2146. View Scientific Paper →
Kazim SF, Chuang SC, Zhao W, Wong RKS, Bianchi R, Iqbal K. Inhibition of AMD-like pathology with a neurotrophic compound in aged rats and 3xTg-AD mice. Front Aging Neurosci. 2019;11:309. View Scientific Paper →